Abbott Laboratories : Solvay Pharmaceuticals Dealogic Deal #  : 617550
Data as of : 9/29/2009
Target Acquiror Dates & Values
Solvay Pharmaceuticals Abbott Laboratories
Target: 100 % stake Buying: 100 % stake Rumored 1st Apr 2009 Deal Value $m 7,638.6
Unlisted 0 0 m shares outstanding Public (Listed) Announced 28th Sep 2009 Value ex Debt $m 7,051.0
Netherlands United States
Healthcare Healthcare Expected 1Q 2010 Consideration
Citigroup | Advisor Barclays Capital | Advisor Completed -
Rothschild | Advisor Cleary Gottlieb | Attorney
Morgan Stanley | Advisor Withdrawn -
Deutsche Bank | Fairness Opinion
Freshfields Bruckhaus | Attorney Termination Fee, Target $m tbd
Termination Fee, Acquiror $m tbd
Financials -
Balance Sheet Debt/Equity: -
Timeline Events Premiums & Multiples
Initial Offer $0.00
Current Offer -
Income Statement
Cash Flows
Operations $m 0
Profitability
Profit Margin -
Return on Equity -
League Table Impact Sector Trend
2009 YTD Announced Global M&A by Deal Value, $bn Monthly Announced Global M&A, $bn: Healthcare
1 Goldman Sachs 470.1
2 Morgan Stanley 459.2
3 JPMorgan 410.1
4 Citi 360.8
5 BOA Merrill Lynch 289.1
6 Lazard 272.7
7 Deutsche Bank 268.4
8 UBS 229.5
9 Credit Suisse 184.6
10 Barclays Capital 160.4
12 Rothschild 97.5
© 2009 Dealogic.  All rights reserved.